Leukemia by Geary, C.G.
Br. J. Cancer, (1984) 49, 399-400
BOOK REVIEWS
Leukemia. FREDRICK W. GuNz & EDWARD S.
HENDERSON, New York, Grune & Stratton, 986
pp, 1983, $99.50, ISBN 0 8089 1513 4.
It is a quarter of a century since the first edition of
this book appeared, and some ten years since the
3rd edition. The earlier texts were almost entirely
the work of two or three authors, but the present
edition differs from its predecessors in being a
multi-author work. Dr E.S. Henderson now joins
Dr F.W. Gunz as principal editor, following the
untimely death of Dr A.G. Baikie. Twenty six
experts, both clinicians and laboratory workers, and
from several different countries, ensure that the
whole field of leukaemia is adequately covered.
Among new chapters are those on the cytogenetics
(Dr O.M. Garson) ultrastructure (Dr J. Breton
Gorius) and immunology (Dr Jun Minowada) of
leukaemic cells: on retro-viruses and leukaemia
(Drs Flossie Wong-Staal and Robert Gallo) and on
leukaemia due to cytotoxic drugs (Drs Fred Rosner
and Hans Grunwald). Dr A.S.D. Spiers takes over
from Dr Gunz the chapter on chronic granulocytic
leukaemia, while Dr Daniel Catovsky contributes
new sections on hairy cell leukaemia and
prolymphocytic leukaemia. Another new feature is
the use of colour microphotographs to illustrate the
morphology and cytochemistry of leukaemic cells,
incorporated into the chapter by Dr John M.
Bennett. The quality of these is acceptable if not,
perhaps, quite up to the standard of some recent
atlases of blood cell morphology. The editors have
now defined the term "leukaemia" more
exclusively: thus, the sections on malignant
lymphoma, and on myeloma and the paraprotein-
aemias have been omitted from this new edition,
while the chronic myeloproliferative disorders are
considered only in the context of pre-leukaemia.
The expanded section on treatment now includes a
succinct and authoritative account of the role of
bone marrow transplantation in leukaemia (Drs
E.D. Thomas and A. Fefer); in his interesting
chapter on acute myelocytic leukaemia, Dr Harvey
Preisler speculates on new therapeutic regimes for
that majority of patients who are not at present
candidates for allogeneic transplantation.
The editors have done their best to impose
uniformity of style in presentation, but, inevitably
in a book with so many contributors, there is some
repetition, and occasionally conflicting views are
expressed - for example the term "pre-leukaemia"
is defined in different ways. On the other hand, it is
curious that, in the section on animal models of
leukaemia, the natural history of murine erythro-
leukaemia due to the Friend virus is not discussed.
The use of inducing agents to promote maturation
of this leukaemic cell line may well be relevant to
the treatment of some forms of smouldering myelo-
blastic leukaemia in man. Discoveries in leukaemic
cell biology are proceeding at an astonishing speed,
and it is a reminder of this that, in a book
published in 1983, the term "oncogene" does not
appear anywhere in the text - though there are
tantalising hints in the chapter by Drs Wong Staal
and Gallo! The human T-cell leukaemia virus is
mentioned, but its epidemiological associations are
not discussed.
These are but minor criticisms, though, and the
editors are to be congratulated on producing
another scholarly yet most readable edition of an
established work. The original senior author, Dr
William Dameshek, described his editorial philo-
sophy in the preface to the first edition: "neither an
encyclopedia, nor a text book, but a monograph
for those... wishing to know more about leukemia
as a whole". The 4th edition fulfills these criteria in
the spirit in which they were conceived.
C.G. Geary
Dept. Clinical Haematology,
Manchester Royal Infirmary,
Manchester.
Interferon and cancer. KAROL SIKORA, UK, Plenum
Press, viii+ 215 pp, 1983, £37.50, 0 306 41379 5.
The interferons (IFN) were discovered over 25
years ago and the media have distorted their
importance, as anticancer agents, beyond the fact.
Many believe that IFN is a drug with proven
efficacy against cancer and viral infections. Because
of this, there cannot be a clinician who deals with
cancer patients who has not, at some time, been
asked about its availability. Yet, except for those of
us who work in clinical oncology, few clinicians will
be completely "au fait" with the results of clinical
research into IFN. Their views will be largely
prejudiced by their reading of the popular press.
The application of modern molecular biological
techniques to the area of IFN production means
that for the first time, highly pure IFNs may be
produced in virtually unlimited amounts. These
substances are currently undergoing Phase I/II
testing and will shortly become more widely
available. It is therefore becoming increasingly
important that clinicians who deal with cancer are